NEW YORK, Feb. 10, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...

Oppenheimer lowered the firm’s price target on Alumis (ALMS) to $26 from $32 and keeps an Outperform rating on the shares. The firm says the ...

News last week including US biotechs Alumis and Acelyrin announcing that they are merging to create a late-stage clinical ...

Rowley Law PLLC is investigating potential securities law violations by ACELYRIN, INC. and its board of directors concerning the proposed acquisition of the company by Alumis Inc. . Stockholders will ...

President Trump’s first term was bad,” he said, “but nobody knows what’s coming. … This is truly nationalism at its worst, because he won on the campaign [largely] to protect American jobs, claiming ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

H.C. Wainwright analyst Mitchell S. Kapoor revised the price target on Alumis Inc (NASDAQ:ALMS) to $19.00, down from the previous target of $26.00, while retaining a Buy rating for the company's ...

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...